Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer
- Author
- HEYMACH, John V; JOHNSON, Bruce E; KENNEDY, Sarah J; HOU, Jeannie; HERBST, Roy S; PRAGER, Diane; CSADA, Edit; ROUBEC, Jaromir; PESEK, Milos; SPASOVA, Irena; BELANI, Chandra P; BODROGI, Istvdn; GADGEEL, Shirish
[1] Dana-Farber Cancer Institute, Boston, MA, United States
[2] UCLA Medical Center, Los Angeles, CA, United States
[3] University of Szeged, Szeged, Hungary
[4] National Institute of Oncology, Budapest, Hungary
[5] University Hospital Ostrava-Poruba, Ostrava, Czech Republic
[6] University Hospital, Medical Faculty in Pilsen, Charles University, Prague, Czech Republic
[7] Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
[8] Wayne State University/Karmanos Cancer Institute, Detroit, MI, United States
[9] AstraZeneca, Alderley Park, Macclesfield, United Kingdom
[10] Astra-Zeneca, Wilmington, DE, United States
[11] University of Texas M.D. Anderson Cancer Center, Houston, TX, United States - Source
Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4270-4277, 8 p ; ref : 29 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Cancer du poumon Cancérologie Carcinome non petite cellule bronchopulmonaire Docétaxel Essai clinique phase II Placebo Randomisation Traitement Vandétanib Antimitotique Appareil respiratoire pathologie Bronche pathologie Poumon pathologie Taxane dérivé Tumeur maligne
- Keyword (en)
- Antineoplastic agent Lung cancer Cancerology non-small cell lung carcinoma Docetaxel Phase II trial Placebo Randomization Treatment Vandetanib Antimitotic Respiratory disease Bronchus disease Lung disease Taxane derivatives Malignant tumor
- Keyword (es)
- Anticanceroso Cáncer del pulmón Cancerología Carcinoma no pequeňa célula bronchopulmonar Docetaxel Ensayo clínico fase II Placebo Aleatorización Tratamiento Vandetanib Antimitótico Aparato respiratorio patología Bronquio patología Pulmón patología Taxane derivado Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pulmonology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 19132965
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2006.10.5122 
https://dx.doi.org/10.1200/JCO.2006.10.5122
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5122\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"27\";s:8:\"\u0000*\u0000spage\";s:4:\"4270\";s:8:\"\u0000*\u0000epage\";s:4:\"4277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HEYMACH\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:16:\"JOHNSON, Bruce E\";i:1;s:16:\"KENNEDY, Sarah J\";i:2;s:12:\"HOU, Jeannie\";i:3;s:13:\"HERBST, Roy S\";i:4;s:13:\"PRAGER, Diane\";i:5;s:11:\"CSADA, Edit\";i:6;s:15:\"ROUBEC, Jaromir\";i:7;s:12:\"PESEK, Milos\";i:8;s:14:\"SPASOVA, Irena\";i:9;s:17:\"BELANI, Chandra P\";i:10;s:15:\"BODROGI, Istvdn\";i:11;s:16:\"GADGEEL, Shirish\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5122\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"27\";s:8:\"\u0000*\u0000spage\";s:4:\"4270\";s:8:\"\u0000*\u0000epage\";s:4:\"4277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HEYMACH\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:16:\"JOHNSON, Bruce E\";i:1;s:16:\"KENNEDY, Sarah J\";i:2;s:12:\"HOU, Jeannie\";i:3;s:13:\"HERBST, Roy S\";i:4;s:13:\"PRAGER, Diane\";i:5;s:11:\"CSADA, Edit\";i:6;s:15:\"ROUBEC, Jaromir\";i:7;s:12:\"PESEK, Milos\";i:8;s:14:\"SPASOVA, Irena\";i:9;s:17:\"BELANI, Chandra P\";i:10;s:15:\"BODROGI, Istvdn\";i:11;s:16:\"GADGEEL, Shirish\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5122\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5122\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"27\";s:8:\"\u0000*\u0000spage\";s:4:\"4270\";s:8:\"\u0000*\u0000epage\";s:4:\"4277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HEYMACH\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:16:\"JOHNSON, Bruce E\";i:1;s:16:\"KENNEDY, Sarah J\";i:2;s:12:\"HOU, Jeannie\";i:3;s:13:\"HERBST, Roy S\";i:4;s:13:\"PRAGER, Diane\";i:5;s:11:\"CSADA, Edit\";i:6;s:15:\"ROUBEC, Jaromir\";i:7;s:12:\"PESEK, Milos\";i:8;s:14:\"SPASOVA, Irena\";i:9;s:17:\"BELANI, Chandra P\";i:10;s:15:\"BODROGI, Istvdn\";i:11;s:16:\"GADGEEL, Shirish\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5122\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"27\";s:8:\"\u0000*\u0000spage\";s:4:\"4270\";s:8:\"\u0000*\u0000epage\";s:4:\"4277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HEYMACH\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:16:\"JOHNSON, Bruce E\";i:1;s:16:\"KENNEDY, Sarah J\";i:2;s:12:\"HOU, Jeannie\";i:3;s:13:\"HERBST, Roy S\";i:4;s:13:\"PRAGER, Diane\";i:5;s:11:\"CSADA, Edit\";i:6;s:15:\"ROUBEC, Jaromir\";i:7;s:12:\"PESEK, Milos\";i:8;s:14:\"SPASOVA, Irena\";i:9;s:17:\"BELANI, Chandra P\";i:10;s:15:\"BODROGI, Istvdn\";i:11;s:16:\"GADGEEL, Shirish\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2006.10.5122\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:2:\"27\";s:8:\"\u0000*\u0000spage\";s:4:\"4270\";s:8:\"\u0000*\u0000epage\";s:4:\"4277\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:7:\"HEYMACH\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John V\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:16:\"JOHNSON, Bruce E\";i:1;s:16:\"KENNEDY, Sarah J\";i:2;s:12:\"HOU, Jeannie\";i:3;s:13:\"HERBST, Roy S\";i:4;s:13:\"PRAGER, Diane\";i:5;s:11:\"CSADA, Edit\";i:6;s:15:\"ROUBEC, Jaromir\";i:7;s:12:\"PESEK, Milos\";i:8;s:14:\"SPASOVA, Irena\";i:9;s:17:\"BELANI, Chandra P\";i:10;s:15:\"BODROGI, Istvdn\";i:11;s:16:\"GADGEEL, Shirish\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:123:\"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
